Cancer Research Horizons and Karolinska Institutet announce 5-year partnership

Working together, both partners will drive forward a shared long-term strategy of promoting and supporting industry collaborations, aiding in the generation of new scientific discoveries that can be rapidly translated into the clinic. 

Under the terms of this new partnership, the parties have committed to several joint activities including research collaborations and funding initiatives, theme-based alliances, mutual access to facilities, expertise, materials, and tools, as well as joint events, and training programmes.  

A major focus of the partnership will be on accessing each other’s networks and collaboration partners to enable the validation and translation of novel targets and mechanisms. 

The partnership also provides the mechanism for Karolinska Institutet researchers to access the Cancer Research Horizons AstraZeneca Antibody Alliance Lab (“AAL”)* to use AstraZeneca’s phage display technology to undertake drug discovery research on novel cancer targets. 

Tony Hickson, Chief Executive Officer for Cancer Research UK and Cancer Research Horizons said: “Not enough promising treatments are reaching cancer patients fast enough. In order to maximise patient benefit from the world-class research we fund, we need to accelerate its translation into clinical practice. But we can’t do this alone and need expert partners like the Karolinska Institutet to join us in our efforts to beat cancer. This is why we are incredibly excited to have the opportunity to collaborate with them over the next five years.”   

Martin Bergö, Academic Vice President for Research said: “The Karolinska Institutet has the vision to advance knowledge about life and strive towards better health for all. Delivering on this vision requires close collaboration with multiple different organisations. We are particularly excited by the opportunities that will arise from our new partnership with Cancer Research Horizons when it comes to realizing our ambitions to translate basic and clinical research knowledge into meaningful therapies for cancer patients.”